NASDAQ:BLTE Belite Bio (BLTE) Stock Price, News & Analysis → READ THIS – If You Missed Out On The AI Boom (From Banyan Hill Publishing) (Ad) Free BLTE Stock Alerts $40.60 -0.33 (-0.81%) (As of 04/30/2024 ET) Add Compare Share Share Today's Range$39.08▼$40.6050-Day Range$32.33▼$47.0552-Week Range$11.00▼$48.60Volume18,952 shsAverage Volume27,424 shsMarket Capitalization$1.18 billionP/E RatioN/ADividend YieldN/APrice Target$44.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Belite Bio alerts: Email Address Belite Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside10.4% Upside$44.83 Price TargetShort InterestHealthy0.12% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.57Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.63) to ($0.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.56 out of 5 starsMedical Sector676th out of 917 stocksPharmaceutical Preparations Industry310th out of 425 stocks 2.5 Analyst's Opinion Consensus RatingBelite Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBelite Bio has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.12% of the outstanding shares of Belite Bio have been sold short.Short Interest Ratio / Days to CoverBelite Bio has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Belite Bio has recently decreased by 13.04%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBelite Bio does not currently pay a dividend.Dividend GrowthBelite Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLTE. Previous Next 3.1 News and Social Media Coverage News SentimentBelite Bio has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Belite Bio this week, compared to 1 article on an average week.MarketBeat Follows3 people have added Belite Bio to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Belite Bio insiders have not sold or bought any company stock.Percentage Held by Insiders13.29% of the stock of Belite Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 0.53% of the stock of Belite Bio is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Belite Bio are expected to decrease in the coming year, from ($0.63) to ($0.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Belite Bio is -32.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Belite Bio is -32.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBelite Bio has a P/B Ratio of 12.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Belite Bio Stock (NASDAQ:BLTE)Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.Read More BLTE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BLTE Stock News HeadlinesApril 27, 2024 | investing.comBelite Bio secures $25 million in registered direct offeringApril 25, 2024 | globenewswire.comBelite Bio Announces $25 Million Registered Direct OfferingMay 1, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.April 23, 2024 | americanbankingnews.comBelite Bio (BLTE) vs. The Competition Critical SurveyApril 13, 2024 | morningstar.comBelite Bio Inc ADRMarch 23, 2024 | finanznachrichten.deBelite Bio, Inc: Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in JapanMarch 22, 2024 | msn.comBelite Retreats On Start Of Clinical TrialMarch 22, 2024 | markets.businessinsider.comBuy Rating Affirmed on Belite Bio as Tinlarebant Shows Promising Clinical Advancements and Market PotentialMay 1, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.March 22, 2024 | globenewswire.comBelite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in JapanMarch 21, 2024 | markets.businessinsider.comBuy Rating Justified for Belite Bio, Inc. ADR Amidst Promising DRAGON Trial Progress and Strong FinancialsMarch 20, 2024 | finance.yahoo.comHere's Why We're Not Too Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn SituationMarch 14, 2024 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Belite Bio, Inc. ADR (BLTE), Catalyst Pharma (CPRX)March 14, 2024 | nasdaq.comBelite Bio is Now Oversold (BLTE)March 14, 2024 | seekingalpha.comBelite Bio, Inc (BLTE) Q4 2023 Earnings Call TranscriptMarch 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Belite Bio, Inc. ADR (BLTE) and Prothena (PRTA)March 11, 2024 | globenewswire.comBelite Bio Announces Availability of Annual Report on Form 20-F Through Company WebsiteMarch 11, 2024 | globenewswire.comBelite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 6, 2024 | globenewswire.comBelite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial ResultsMarch 4, 2024 | globenewswire.comBelite Bio to Participate in the Leerink Partners Global Biopharma ConferenceFebruary 21, 2024 | benzinga.comBelite Bio Stock (NASDAQ:BLTE) Insider TradesFebruary 7, 2024 | finance.yahoo.comBelite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceJanuary 9, 2024 | finance.yahoo.comIs There An Opportunity With Belite Bio, Inc's (NASDAQ:BLTE) 49% Undervaluation?December 28, 2023 | markets.businessinsider.comBuy Rating for Belite Bio Backed by Tinlarebant’s Promising Global Trials and Safety ProfileDecember 28, 2023 | benzinga.comBelite Bio Stock (NASDAQ:BLTE) Dividends: History, Yield and DatesNovember 30, 2023 | finance.yahoo.comBelite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor ConferenceNovember 20, 2023 | finance.yahoo.comBelite Bio to Participate in the BTIG Ophthalmology DaySee More Headlines Receive BLTE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Belite Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/11/2024Today5/01/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BLTE CUSIPN/A CIK1889109 Webbelitebio.com Phone858-246-6240FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$44.83 High Stock Price Target$60.00 Low Stock Price Target$25.00 Potential Upside/Downside+10.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,630,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-54.05% Return on Assets-50.06% Debt Debt-to-Equity RatioN/A Current Ratio24.76 Quick Ratio24.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.28 per share Price / Book12.38Miscellaneous Outstanding Shares29,150,000Free Float25,275,000Market Cap$1.18 billion OptionableNot Optionable Beta-1.62 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Yu-Hsin Lin M.B.A. (Age 45)Ph.D., Chairman of the Board of Directors & CEO Mr. Hao-Yuan Chuang C.F.A. (Age 39)F.R.M., M.B.A., CFO & Director Dr. Nathan L. Mata Ph.D. (Age 57)Chief Scientific Officer Key CompetitorsMirum PharmaceuticalsNASDAQ:MIRMSpyre TherapeuticsNASDAQ:SYRECollegium PharmaceuticalNASDAQ:COLLIronwood PharmaceuticalsNASDAQ:IRWDPacira BioSciencesNASDAQ:PCRXView All CompetitorsInstitutional OwnershipArmistice Capital LLCBought 36,000 shares on 2/13/2024Ownership: 0.130%Jump Financial LLCBought 5,200 shares on 2/7/2024Ownership: 0.019%View All Institutional Transactions BLTE Stock Analysis - Frequently Asked Questions Should I buy or sell Belite Bio stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Belite Bio in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BLTE shares. View BLTE analyst ratings or view top-rated stocks. What is Belite Bio's stock price target for 2024? 7 equities research analysts have issued 1 year target prices for Belite Bio's stock. Their BLTE share price targets range from $25.00 to $60.00. On average, they expect the company's stock price to reach $44.83 in the next year. This suggests a possible upside of 10.4% from the stock's current price. View analysts price targets for BLTE or view top-rated stocks among Wall Street analysts. How have BLTE shares performed in 2024? Belite Bio's stock was trading at $45.75 on January 1st, 2024. Since then, BLTE stock has decreased by 11.3% and is now trading at $40.60. View the best growth stocks for 2024 here. Are investors shorting Belite Bio? Belite Bio saw a decrease in short interest in the month of April. As of April 15th, there was short interest totaling 34,000 shares, a decrease of 13.0% from the March 31st total of 39,100 shares. Based on an average trading volume of 52,300 shares, the days-to-cover ratio is currently 0.7 days. View Belite Bio's Short Interest. When is Belite Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our BLTE earnings forecast. How were Belite Bio's earnings last quarter? Belite Bio, Inc (NASDAQ:BLTE) issued its quarterly earnings data on Monday, March, 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.11. When did Belite Bio IPO? Belite Bio (BLTE) raised $36 million in an initial public offering (IPO) on Friday, April 29th 2022. The company issued 6,000,000 shares at $5.50-$6.50 per share. How do I buy shares of Belite Bio? Shares of BLTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BLTE) was last updated on 5/1/2024 by MarketBeat.com Staff From Our PartnersElon’s New A.I. Device is About to Shock the WorldInvestorPlaceAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market Insiders😱 This phenomenon is smashing regular market gainsMillPubYour bank is lying to you.MyBankTracker#1 election stockPorter & CompanyBiden to Launch “FedNOW” [Move Your Money Now]Priority Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Belite Bio, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
